Poniard Plans 2009 NDA For “New Generation” Platinum-Based Chemotherapy Picoplatin
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes ongoing studies will support three-pronged safety and efficacy benefit showing the oncologic overcomes platinum resistance, is neuropathy sparing and combines well with other treatments.